A Warfarin, sodium deriv CEP of the European Pharmacopoeia monograph is often referred to as a Warfarin, sodium deriv Certificate of Suitability (COS). The purpose of a Warfarin, sodium deriv CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Warfarin, sodium deriv EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Warfarin, sodium deriv to their clients by showing that a Warfarin, sodium deriv CEP has been issued for it. The manufacturer submits a Warfarin, sodium deriv CEP (COS) as part of the market authorization procedure, and it takes on the role of a Warfarin, sodium deriv CEP holder for the record. Additionally, the data presented in the Warfarin, sodium deriv CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Warfarin, sodium deriv DMF.
A Warfarin, sodium deriv CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Warfarin, sodium deriv CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Warfarin, sodium deriv suppliers with CEP (COS) on PharmaCompass.